Cranberry

Vaccinium macrocarpon — the North American berry, weighed by extract-equivalent

All articles checked for accuracy against the GB NHC Register and all sources have citations with verified links to their relevant studies.

Cranberry (Vaccinium macrocarpon) is a much-studied berry whose distinctive A‑type proanthocyanidins (PACs) drive most research interest. The evidence is complex: laboratory studies, regulatory assessments and recent reviews do not all say the same thing.

This article explains what cranberry is, which compounds researchers focus on, how WellsparQ declares its extract-equivalent weight, and why the scientific picture remains mixed. It highlights regulatory context so readers get an honest, compliant account rather than overstated promise.

Ingredient Snapshot

What it is

A tart red berry from the Vaccinium family, used as a concentrated extract.

Where from

Vaccinium macrocarpon — North American cranberry, extract-equivalent.

Known for

Contains A-type proanthocyanidins (PACs), anthocyanins and vitamin C; research findings are mixed.

In WellsparQ

• Mannose Max2,160 mg (extract-equivalent)

Cranberry is one of the most heavily studied berries in the supplement world — and, revealingly, one of the most argued-over. Its evidence base is a genuinely useful case study in how careful you have to be: two respected bodies looking at the same plant have reached different-sounding conclusions. WellsparQ includes cranberry at a substantial extract-equivalent weight, names the species, and — as ever — lets the research speak for itself without turning any of it into a promise.

The berry and its chemistry

Cranberry is the fruit of Vaccinium macrocarpon, a low, trailing evergreen native to the bogs and wetlands of North America and long harvested there ^¹. The berries are tart, deep red, and unusually rich in a particular family of polyphenols.

The compound cranberry is studied for is its A-type proanthocyanidins (PACs) — condensed tannins whose distinctive "A-type" chemical linkage sets them apart from the "B-type" PACs in most other fruits ^²³. It is this structural quirk that the research literature has focused on. Cranberry also carries anthocyanins, flavonols, organic acids and vitamin C, but PAC content is the marker most extracts are standardised to ^².

Source: WellsparQ Supplements Database. Cranberry sits here alongside D-Mannose. As a fruit-derived material it fits the brand's vegan, kosher and halal standard.

The evidence — told straight

This is where cranberry gets interesting, and where honesty matters most.

The mechanism most cited is that A-type PACs may interfere with the ability of certain E. coli bacteria (the P-fimbriated type) to adhere to the cells lining the urinary tract ^²³. That is a plausible, well-described laboratory observation.

EFSA's verdict on the claim. When European regulators assessed cranberry PACs for a formal health claim, they were not satisfied. In 2011 the EFSA panel concluded that a cause-and-effect relationship had not been established between cranberry PAC consumption and defence against urinary-tract bacteria, and the claim was not authorised ^². Several later company-specific cranberry submissions were likewise unsuccessful.

The Cochrane verdict has shifted. Systematic reviewers have gone back and forth as trials accumulated. Earlier Cochrane assessments concluded the benefit looked small and that cranberry "could not be recommended." The most recent 2023 Cochrane review, however — pooling 45 randomised trials — concluded that cranberry products reduced the number of urinary-tract infections in women with recurrent infections, in children, and in people made susceptible by an intervention such as bladder radiotherapy, while finding little effect in elderly or catheter-using groups ^⁴. It is a more favourable read than a decade earlier, though reviewers still note variability in product type and dose.

The fair, WellsparQ way to summarise all this: the science is active and genuinely mixed. Regulators have not authorised a claim; the latest high-quality evidence synthesis is cautiously more positive in specific groups. Both facts are true, and we report both. Neither becomes an on-page promise.

Why standardisation and weight matter

The single biggest reason cranberry trials disagree is that "cranberry" has meant wildly different things — sweetened juice, unstandardised powder, or a PAC-standardised extract — at very different doses ^³⁴. This is exactly why an extract-equivalent declaration and a stated species are worth having: they tell you what you're actually taking, rather than leaving "cranberry" as a vague word on a label. WellsparQ's 2,160 mg equivalent is declared for that reason.

Sensible use

Cranberry is a food with a long safety record. Concentrated supplements are generally well tolerated; the main practical caution is a well-documented interaction with warfarin, where cranberry has been associated with altered anticoagulant effect, so anyone on warfarin should speak to their prescriber ^¹. Very large intakes can cause stomach upset, and people prone to kidney stones are sometimes advised caution because of oxalate content ^¹. Cranberry supplements do not treat an established infection — genuine urinary symptoms need proper medical advice.